Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis

Stillger, Maren Nicole; Chen, Chia-Yi; Lai, Zon Weng; Li, Mujia; Schäfer, Agnes; Pagenstecher, Axel; Nimsky, Christopher; Bartsch, Jörg Walter; Schilling, Oliver

doi:10.1186/s12935-023-02889-8

Table 2 Clinical data for GBM patients included in the calpain mRNA expression profiling

From: Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis

Patient	Sex	Survival [days]	Tumor	MGMT status	EGFR v III	IDH r132H	Tp53	Ki67 [%]
1	m	511	Initial	Unmethylated	Negative	Negative	0	25
			Recurrent	Unmethylated	Negative	Negative	+ +	10
2	m	553	Initial	Unmethylated	Negative	Negative	+ +	20
			Recurrent	Unmethylated	Negative	Negative	+ +	30
3	m	543	Initial	Unmethylated	Negative	Negative	−	30
			Recurrent	Unmethylated	Negative	Negative	−	30
4	m	371	Initial	Unmethylated	Negative	Negative	−	25
			Recurrent	Unmethylated	Negative	Negative	+	10
5	m	387	Initial	Unmethylated	Negative	Negative	0	50
			Recurrent	Unmethylated	Negative	Negative	+	25
6	m	760	Initial	Unmethylated	Focal exp	Negative	Focal +	75
			Recurrent	Unmethylated	Negative	Negative	Focal +	20
7	f	445	Initial	Unmethylated	Negative	Negative	Partial +	20
			Recurrent	Unmethylated	Negative	Negative	+	5
8	m	343	Initial	Unmethylated	Negative	Negative	+	50
			Recurrent	Unmethylated	Negative	Negative	+ +	10
9	f	550	Initial	Unmethylated	Negative	Negative	+ +	15
			Recurrent	Unmethylated	Focal exp	Negative	0	7
10	m	524	Initial	Unmethylated	Negative	Negative	0	25
			Recurrent	Unmethylated	Negative	Negative	+ +	5
11	f	1277	Initial	Methylated	Negative	Negative	+ +	50
			Recurrent	Methylated	Negative	Negative	+	40
12	f	494	Initial	Unmethylated	Negative	Negative	+ +	10
			Recurrent	Unmethylated	Negative	Negative	+ +	20
13	m	576	Initial	Unmethylated	Negative	Negative	−	30
			Recurrent	Unmethylated	Negative	Negative	+	5
14	f	1997	Initial	Unmethylated	Negative	Negative	+	10
			Recurrent	Unmethylated	Negative	Negative	+	20
15	f	679	Initial	Unmethylated	Negative	Negative	0	40
			Recurrent	Unmethylated	Negative	Negative	+	50
16	f	869	Initial	Methylated	Negative	Negative	+	30
			Recurrent	Methylated	Negative	Negative	+	5
17	m	457	Initial	Unmethylated	Negative	Negative	+ +	20
			Recurrent	Unmethylated	Negative	Negative	−	3
18	f	328	Initial	Methylated	Negative	Negative	+ +	20
			Recurrent	Methylated	Negative	Negative	+	10
19	m	1624	Initial	Unmethylated	Negative	Negative	+ +	40
			Recurrent	Unmethylated	Negative	Negative	+ +	5

TP53 status: + + strong accumulation, + accumulation, 0 moderate accumulation,—weak accumulation

Back to article page

ISSN: 1475-2867

Contact us

General enquiries: journalsubmissions@springernature.com

Cancer Cell International

Contact us